Clinical Efficacy Of Different Doses And Different Types Of Statins In Acute Coronary Syndrome Patients At Acute Phase

Objective:(1)To investigate the efficacy of lipid- lowering drugs of statin in acute coronary syndrome(ACS) patients at acute phase.(2)To compare the efficacy of different doses and different types of statin in acute coronary syndrome(ACS) patients at acute phase,and provide some evidences for clinical drug therapy.(3)To observe the safety of different doses and different types of statin.Methods:Clinical data of 133 ACS patients(110 males and 23 females) hospitalized in our cardiovascular medicine department in Southwest Hospital of the Third Military Medical University from January 2012 to June 2014 were collected and retrospectively analyzed.These patients were divided into 4 groups, which accorded to the patients received different types and doses of statin for treatment. Group A : for 32 patients were treated with rosuvastatin of 10 mg/d, group B :37 patients were treated with rosuvastatin of 20 mg/d, group C,33 patients were treated with atorvastatin of 20 mg/d, and group D: 31 patients were treated with atorvastatin of 40 mg/d.The serum levels of low density lipoprotein cholesterol(LDL-C), total cholesterol(TC) and non-high-density lipoprotein cholesterol(non-HDL-C),and the incidences of adverse reactions were compared and analyzed in 4 group before and in 6 to 8 weeks after the treatment,and among different groups.Results:(1) Before the treatment, there was no significant difference about hypertension, diabetes, smoking history, UA, AMI and medication among the 4 groups( P>0.05).(2) There was no significant difference about the serum lipoprotein cholesterol leve ls of TC、TG、LDL-C、HDL-C and non-HDL-C among the 4 groups, which was before the treatment(P>0.05).(3) After 6 to 8 weeks’ treatment, the serum levels of TC、LDL-C、non-HDL-C were dropped statistically in all groups(P<0.01).(4) △ LDL-C means the reduced degree of LDL-C concentration changing during before the treatment and 6 to 8 weeks after treatment. There were significantly larger in groups B and D than groups A and C(P<0.01), but there was no significant difference between group B and group D(P>0.05).△ non-HDL-C means the reduced degree of non-HDL-C concentration changing during before the treatment and 6 to 8 weeks after treatment. There were significantly larger in groups B and D than groups A and C(P<0.01), but there was no significant difference between group B and group D(P>0.05).(5) During the treatment, only 1 patient from group B had ALT significant increase more than 3 times of upper normal limit, from 33 U/L to 1120 U/L. And there was no report of adverse reactions in other groups.Conclusion:(1) The lipid- lowering drugs of statin can effectively reduce the level of blood lipids in ACS patients at acute phase.(2) High-dose statin(rosuvastatin 20 mg/d and atorvastatin 40 mg/d)treatment in superior to conventional-dose statin(rosuvastatin 10 mg/d and atorvastatin 20 mg/d) on the patients at acute phase of ACS.(3) Different doses of rosuvastatin and atorvastatin have good safety at the same time.